Intravenous tenecteplase in acute ischemic stroke: an updated review.

Abstract

Tenecteplase in a genetically engineered variant of alteplase. Although the two have the same mechanism of action, tenecteplase has properties that makes it a seemingly more advantageous thrombolytic. Because of its rapid single-bolus administration, its use is favored over alteplase in the treatment of acute myocardial infarction. Over the past few years, several clinical studies have been conducted to assess the safety, feasibility, and efficacy of tenecteplase in ischemic stroke. In spite of the mixed results of these studies, experimentation with tenecteplase continues in from of clinical trials. In this article, the utility of tenecteplase in ischemic stroke will be discussed.

• Authors: Réza Behrouz
• Journal: Journal of neurology (J Neurol) Vol. 261 Issue 6 Pg. 1069-72 (Jun 2014) ISSN: 1432-1459 [Electronic] Germany
• PMID: 24036924 (Publication Type: Journal Article, Review)

Chemical References

• Fibrinolytic Agents
• Tissue Plasminogen Activator
• Tenecteplase

Topics

• Administration, Intravenous
• Fibrinolytic Agents (administration & dosage)
• Humans
• Ischemia (complications)
• Stroke (drug therapy, etiology)
• Tenecteplase
• Tissue Plasminogen Activator (administration & dosage)